Trastuzumab emtansine
- CAS No.
- 1018448-65-1
- Chemical Name:
- Trastuzumab emtansine
- Synonyms
- T-DM1;Kadcyla;PRO132365;trastuzumab-DM1;trastuzumab-MCC-DM1;trastuzumab emtansine;Ado-trastuzumab emtansine;Ado-trastuzuMab-eMtansine cas nr;Ado-trastuzumab Emtansine (TDM-1);trastuzumab-MCC-DM1 antibody-drug conjugate
- CBNumber:
- CB12672561
- Molecular Formula:
- Molecular Weight:
- 0
- MOL File:
- Mol file
- MSDS File:
- SDS
- Modify Date:
- 2024/7/2 8:55:00
SAFETY
Risk and Safety Statements
| Symbol(GHS) |    GHS08,GHS07,GHS06 |
|---|---|
| Signal word | Danger |
| Hazard statements | H300-H371-H315-H360-H351-H340-H330 |
| Precautionary statements | P264-P270-P301+P310-P321-P330-P405-P501-P260-P264-P270-P309+P311-P405-P501-P264-P280-P302+P352-P321-P332+P313-P362-P201-P202-P281-P308+P313-P405-P501-P260-P271-P284-P304+P340-P310-P320-P403+P233-P405-P501 |
Trastuzumab emtansine Chemical Properties,Uses,Production
Description
T-DM1 is a human epidermal growth factor receptor (HER2)-targeted antibody drug conjugate (ADC) that was approved in February 2013 by the US FDA for use as a single agent for the treatment of patients with HER2-positive, metastatic breast cancer (mBC) who previously received treatment with trastuzumab and a taxane, separately, or in combination. T-DM1 is composed of trastuzumab linked to the potent cytotoxic microtubule polymerization inhibitor DM1 (derivative of maytansine) via a stable uncleavable thioether linker. T-DM1 is produced by chemically crosslinking the cytotoxic maytansinoid derivative to the lysine residues of trastuzumab such that there is an average of 3.5 cytotoxic molecules linked to each antibody. In addition to delivering DM1 to tumor cells, T-DM1 retains the effector functions of trastuzumab, including inhibition of HER2-mediated signal transduction and activation of antibodydependent cell-mediated cytotoxicity.
Originator
Genentech, a member of the Roche Group (United States)
brand name
Kadcyla
Trastuzumab emtansine Preparation Products And Raw materials
Raw materials
Preparation Products
Trastuzumab emtansine Suppliers
| Supplier | Tel | Country | ProdList | Advantage | Inquiry |
|---|---|---|---|---|---|
| Sln Pharma | 08046067049 | Karnataka, India | 2 | 58 | Inquiry |
| Henan Tianfu Chemical Co.,Ltd. | +86-0371-55170693 +86-19937530512 | China | 21671 | 55 | Inquiry |
| BOC Sciences | +1-631-485-4226 | United States | 19553 | 58 | Inquiry |
| Career Henan Chemica Co | +86-0371-86658258 +8613203830695 | China | 30253 | 58 | Inquiry |
| Wuhan Topule Biopharmaceutical Co., Ltd | +8618327326525 | China | 8474 | 58 | Inquiry |
| LEAPCHEM CO., LTD. | +86-852-30606658 | China | 43348 | 58 | Inquiry |
| Wuhan Jingkang en Biomedical Technology Co., Ltd | +8613720134139 | China | 4692 | 58 | Inquiry |
| Hubei wei shi reagent group ltd., company | 027-59102966 18717199209 | China | 5926 | 58 | Inquiry |
| TargetMol Chemicals Inc. | 15002134094 | China | 28118 | 58 | Inquiry |
| Olix (Shanghai) Pharmaceutical Technology Co., Ltd | 17316404525 | China | 9640 | 58 | Inquiry |